Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.

Original languageEnglish (US)
Pages (from-to)2088-2090
Number of pages3
JournalCancer
Volume98
Issue number10
DOIs
StatePublished - Nov 15 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls'. Together they form a unique fingerprint.

  • Cite this